Eli Lilly and Company Company Profile by CMR

Company Profile

Eli Lilly and Company Basic Information, Manufacturing Base, Sales Area, and Competitors

Sr. No.	Item	Description
1	Company Name	Eli Lilly and Company
2	Website	www.lilly.com
3	Established Date	1876
4	Headquartered	United States
5	Market Position/ History	Eli Lilly and Company is a drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. The company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The company’s products are sold in approximately 105 countries. Approximately 10,000 employees engaged in research and development Clinical research conducted in more than 55 countries Research and development facilities located in 7 countries Manufacturing plants located in 9 countries
6	Sales Area	Worldwide
7	Manufacturing Location	United States, Europe, and Asia
8	Ticker	NYSE: LLY
9	No. of Employees	43,000 people
10	Competitors	GSK Bristol Myers Squibb Merck Pfizer GlaxoSmithKline
11	CEO	David A. Ricks
12	Ownership Type	Public
13	Contact Information	Lilly Corporate Center, Indianapolis, IN 46285, United States Tel: 317 276 2000

Business Segment/ Overview:

Eli Lilly and Company is engaged in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. It focuses on neuroscience, cardiometabolic, cancer, and immunology. The company's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Company and Boehringer Ingelheim have a global agreement to develop and commercialize a portfolio of diabetes products, including Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, Basaglar, and Rezvoglar.

Anti-Obesity Drugs Pipeline Product Types Specification

Product	Product Description
Bimagrumab	LY3985863 (Bimagrumab) is a monoclonal antibody that binds the activin/myostatin type II receptors ActRIIA and ActRIIB and blocks ligand binding. It is being studied for the treatment of obesity.
Amylin Agonist Long Acting	"Amylin Agonist Long Acting" is a biological entity being studied for the treatment of obesity.
DACRA QW II	“DACRA QW II" is a biological entity being studied for the treatment of obesity.
Mazdutide	Indication Study: Obesity Status: Phase II (Phase II trial initiated in 2023.) LY3305677 (Mazdutide) is a mammalian oxyntomodulin (OXM) analogue that acts as a glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist. It is being studied for the treatment of obesity. Note that simultaneous Ph3 development in China is being conducted by Innovent for T2DM and Obesity.
Orforglipron	LY3502970 (Orforglipron) is a chemical entity that acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor. It is being studied for the treatment of obesity. Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweigh

Recent Developments:

Year

Latest News

8 November 2023

FDA Approved Lilly's Zepbound (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

In November 2023, The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off.

Nisha Deore

Nisha Deore is a highly skilled Research Analyst with over three years of experience specializing in food & beverage sectors. Her expertise encompasses secondary research, data mining, competitive analysis, and…

Previous Profile Currax Pharmaceuticals LLC

Next Profile Rhythm Pharmaceuticals Inc

Profile Details

Author Nisha Deore
Published 11 May 2024
Last Updated 11 May 2024
Reading Time~5 minutes
CoverageSWOT, Financials, Key Employees, History

- 1.1 About Eli Lilly and Company
- 1.2 Key Facts
- 1.3 Key Employees
  - 1.3.1 Key Employee Biographies
- 1.4 History
- 1.5 Locations & Subsidiaries
  - 1.5.1 Head Office
  - 1.5.2 Other Locations & Subsidiaries
- 2.1 Company Overview
- 2.2 Business Segments
- 2.3 R&D Overview
- 2.4 Brands
- 2.5 Key Company Statistics
- 2.6 Key Financials (2015–2019)
- 2.7 Share Holder Analysis
- 2.8 Regional Presence
- 2.9 Services Offered
- 3.1 Strengths
- 3.2 Weaknesses
- 3.3 Opportunities
- 3.4 Threats
- 3.5 Key Competitors
- 4.1 Company Metrics
- 4.2 Key Investors
- 4.3 Recent Funding & Valuation
- 4.4 Historical Funding & Valuation
- 5.1 Acquisitions
- 5.2 Partnerships
- 6.1 Latest News & Announcements
- 6.2 Strategic Initiatives
- 7.1 Summary of Findings
- 7.2 Strategic Recommendations

Get a Custom Profile

Need a tailored company profile or competitive intelligence report? Our analysts are ready to help.

Contact Our Experts

More Profiles

Explore all published company profiles across 30+ industry verticals.

View All Profiles

Eli Lilly and Company Company Profile